Roundtable Discussion; The Future of Mineral Sands. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksNuformix Share News (NFX)

Share Price Information for Nuformix (NFX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.175
Bid: 0.17
Ask: 0.18
Change: -0.01 (-5.41%)
Spread: 0.01 (5.882%)
Open: 0.185
High: 0.00
Low: 0.00
Prev. Close: 0.185
NFX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

WINNERS & LOSERS SUMMARY: 7digital Warns Of Need For Capital Raise

Tue, 09th Apr 2019 10:46

LONDON (Alliance News) - The following stocks are the leading risers and fallers within the main London indices on Tuesday.----------FTSE 100 - WINNERS----------Anglo American, up 0.5%. The miner said its De Beers rough diamond sales in the third sales cycle of 2019 were about 10% higher than the year prior amid "stable" demand. Its third cycle sales in 2019 - as of Tuesday - stood at a provisional USD575 million. This was 9.7% higher than the USD524 million sales reported in the third cycle of 2018 and 16% up on the USD496 million sales reported for the second cycle of 2019.----------FTSE 100 - LOSERS----------Severn Trent, down 2.0%. JPMorgan downgraded the water company to Neutral from Overweight. ----------FTSE 250 - WINNERS----------NewRiver REIT, up 2.5%. The trust declared a fourth-quarter dividend of 5.4 pence per share, which is a 3% increase on the fourth quarterly dividend of 5.25 pence the prior year.----------FTSE 250 - LOSERS----------Pennon Group, down 2.0%. JPMorgan cut the utility stock to Neutral from Overweight. Hays, down 1.5%. Morgan Stanley downgraded the recruiter to Equal Weight from Overweight. Go-Ahead Group, 1.0%. HSBC lowered its rating on the transport operator to Hold from Buy. ----------OTHER MAIN MARKET AND AIM - WINNERS----------Nuformix, up 60%. The pharmaceutical firm said it has signed a cannabinoid therapeutics agreement worth up to GBP51 million with private Canadian company Ebers Tech. The development, licensing and commercialisation agreement contains as much as GBP51 million of upfront, research and development, and milestone payments as well as long-term royalties of 20% of net sales, Nuformix said. Under the agreement, Ebers can use Nuformix's technology platforms to bring therapeutic cannabinoid products to market. Ebers is backed by financial sector leaders with connections to the US cannabinoid market. Nuformix is expecting "a significant upfront payment with further research and development and early-stage milestone payments of up to GBP1 million in 2019. More pre-clinical and milestone payments are likely in 2020 and 2021.Defenx, up 55%. The mobile security software firm said it has signed a software distribution and a software services agreement with majority shareholder BV Tech. The new distribution agreement modifies the terms of a previous deal from 2017. BV Tech - which has a 67% stake in Defenx - now has the sole right to sell Defenx's cyber security products to "bodies within the Italian defence, space, national security or critical infrastructures sector" until the end of 2023. For this, BV Tech will pay EUR1.0 million in three instalments before the end of the first half of 2019 and will also pay a 50% royalty fee to Defenx on any revenue from the sale of its products to clients exceeding EUR5.0 million. BV Tech has also committed, under the distribution agreement, to buy Defenx's products, with a minimal value of EUR1.2 million for a two-year period beginning in January 2019. Prior restrictions have been removed so that BV Tech can now distribute all of Defenx's products on an exclusive basis until the end of 2021. The software services agreement is entirely new. BV Tech will provide software services to Defenx, for which Defenx will pay a maximum of EUR1.2 million. One Media IP Group, up 12%. The digital media content company said annual profit rocketed due to strong streaming demand. The company posted a 63% increase in pretax profit to GBP486,504 for the year ended October 31, 2018, up from GBP297,601 the year before. One Media experienced 17% revenue growth to GBP2.7 million from GBP2.3 million. This was attributed to improved customer demand on streaming platforms, as well as revenue distributions from digital platforms. The company placed some of its music into film and television during its year, with its recording of Chopin's Nocturne Op No 2 in E-Flat Major appearing in Marvel's Daredevil and a new TV series by Jim Carey called 'Kidding'. As at October 31, One Media's cash balance stood at GBP5.6 million versus GBP335,664 the year before. The company added that is "well placed to benefit" from music industry growth and has "a strong pipeline of opportunities".----------OTHER MAIN MARKET AND AIM - LOSERS----------7digital Group, down 63%. The digital music and radio services company warned it requires further funding in the near future to continue trading. Having started a company review, 7digital is taking "a more circumspect" view of its sales pipeline, and it now believes it will need "material" equity or debt funding in the third quarter of 2019. "The board will assess financing options for the company however, it is likely that this would entail significant dilution for shareholders," the company said. As part of the group's new strategy it will no longer be giving a pre-close trading update for 2018, as it decides how to recognise the EUR4.0 million settlement received from MediaMarktSaturn in March. The case related to Media-Saturn subsidiary Juke Entertainment's music service, with Media-Saturn having wanted to end its relationship with 7digital. "The negotiations and ultimate loss of MediaMarktSaturn as a customer prior to John's arrival at the company has diverted management attention and led to disruption within the business during the first quarter as well as having a marked effect on customer sentiment," warned 7digital.Stride Gaming, down 13%. The online gaming operator said its revenue in the first half of its current financial year was lower than expected due to recently implemented regulatory changes. The company expects to report net gaming revenue for the six months to the end of February 5% lower than envisaged due to a disruption from fiscal and regulatory changes in the second half of calendar 2018. However, Stride does now see signs the impact has been largely absorbed and its business model is adjusting accordingly. Looking ahead, the company does not expect to recover the first half revenue shortfall through trading in the second half. Stride expects to report a strong performance from its Stride Together joint venture and is encouraged by further new partnership opportunities.----------

More News
10 Feb 2021 10:18

Nuformix seeks chairman as Blackwell quits after a year

(Sharecast News) - Chris Blackwell has quit as Nuformix's chairman a year after taking the job at the drug development company.

Read more
22 Dec 2020 11:48

IN BRIEF: Nuformix Half-Year Loss Widens As Revenue Plunges 60%

IN BRIEF: Nuformix Half-Year Loss Widens As Revenue Plunges 60%

Read more
7 Dec 2020 15:13

UK EXECUTIVE CHANGE SUMMARY: Nuformix And Sterling Energy Tap New CEOs

UK EXECUTIVE CHANGE SUMMARY: Nuformix And Sterling Energy Tap New CEOs

Read more
2 Dec 2020 14:37

UK EXECUTIVE CHANGE SUMMARY: Accrol Hires New CFO Newman From DS Smith

UK EXECUTIVE CHANGE SUMMARY: Accrol Hires New CFO Newman From DS Smith

Read more
24 Nov 2020 16:27

UK EXECUTIVE CHANGE SUMMARY: Ocean Wilson Long-Time Finance Head Exits

UK EXECUTIVE CHANGE SUMMARY: Ocean Wilson Long-Time Finance Head Exits

Read more
7 Oct 2020 18:20

UK TRADING UPDATE SUMMARY: Gym Group Fighting Fit With Fresh York Unit

UK TRADING UPDATE SUMMARY: Gym Group Fighting Fit With Fresh York Unit

Read more
24 Sep 2020 17:35

UK TRADING UPDATE SUMMARY: Personal Group Lauds Royal Mail Contract

UK TRADING UPDATE SUMMARY: Personal Group Lauds Royal Mail Contract

Read more
19 Aug 2020 15:01

Nuformix Sees Positive Results Of Pilot Study For Fibrosis Programme

Nuformix Sees Positive Results Of Pilot Study For Fibrosis Programme

Read more
22 Jul 2020 19:06

Nuformix Annual Loss Narrows Despite Seeing Revenue Slip

Nuformix Annual Loss Narrows Despite Seeing Revenue Slip

Read more
27 May 2020 13:10

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

UK TRADING UPDATE SUMMARY: Caffyns To Reopen Showrooms As Curbs Ease

Read more
18 Feb 2020 13:14

Nuformix Names HOX Therapeutics CFO Karl Keegan As Non-Exec Director

Nuformix Names HOX Therapeutics CFO Karl Keegan As Non-Exec Director

Read more
5 Feb 2020 17:36

Nuformix Non-Executive Chair Dave Tapolczay Resigns

Nuformix Non-Executive Chair Dave Tapolczay Resigns

Read more
27 Jan 2020 16:04

Nuformix PLC Says Non-Executive Director Lidgey To Step Down

Nuformix PLC Says Non-Executive Director Lidgey To Step Down

Read more
24 Dec 2019 08:30

Nuformix Reports "Significant Progress" In Half-Year As Loss Narrows

Nuformix Reports "Significant Progress" In Half-Year As Loss Narrows

Read more
25 Nov 2019 18:09

Nuformix Raises GBP1.3 Million To Develop Pipeline

Nuformix Raises GBP1.3 Million To Develop Pipeline

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.